FDA public workshop summary: Advancing animal models for antibacterial drug development

James M. Byrne, Ursula Waack, Edward A. Weinstein, Abhay Joshi, Simone M. Shurland, Dmitri Iarikov, Jürgen B. Bulitta, Binh An Diep, Tina Guina, William W. Hope, Matthew B. Lawrenz, Alexander J. Lepak, Brian M. Luna, Lynn Miesel, Andrew J. Phipps, Thomas J. Walsh, William Weiss, Thushi Amini, John J. Farley

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

The U.S. Food and Drug Administration (FDA) hosted a public workshop entitled “Advancing Animal Models for Antibacterial Drug Development” on 5 March 2020. The workshop mainly focused on models of pneumonia caused by Pseudomonas aeruginosa and Acinetobacter baumannii. The program included discussions from academic investigators, industry, and U.S. government scientists. The potential use of mouse, rabbit, and pig models for antibacterial drug development was presented and discussed.

Original languageEnglish
Article numbere01983-20
JournalAntimicrobial agents and chemotherapy
Volume65
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • Animal models
  • Antibacterial
  • Antibiotics
  • Drug development
  • FDA
  • Humanized dose
  • Pneumonia
  • Regulatory
  • Workshop

Fingerprint

Dive into the research topics of 'FDA public workshop summary: Advancing animal models for antibacterial drug development'. Together they form a unique fingerprint.

Cite this